Diffuse Large B-Cell Lymphoma, NOS · line 2 · Polatuzumab vedotin + Rituximab + Bendamustine (Pola-BR), 6 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-POLA-R-BENDAMUSTINE |
| ID | IND-DLBCL-2L-POLA-R-BENDAMUSTINE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L for transplant-ineligible r/r DLBCL. For transplant-eligible patients, IND-DLBCL-2L-RDHAP-AUTOSCT (existing REG-R-DHAP-AUTOSCT regimen) remains the preferred salvage pathway. Polatuzumab access constraint is dominant barrier in Ukraine.
Used By
Algorithms
ALGO-DLBCL-2L- ALGO-DLBCL-2L